Igamad

Human Anti-D Immunoglobulin, the active ingredient in Igamad, is an immunoglobulin presented as a solution for injection for intramuscular use. It prevents Rh alloimmunization in Rh‑negative pregnant women and reduces the risk of hemolytic disease of the newborn.

GNH USA supplies Igamad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Igamad, an anti‑D immunoglobulin, is used in the Rh‑D antigen pathway to prevent maternal sensitization.

Rh‑negative pregnancy: prevents maternal immune sensitization to the D antigen, reducing risk of hemolytic disease of the newborn. Fetal‑maternal hemorrhage: provides passive immunity to avoid alloimmunization after bleeding events. Newborn care: lowers incidence of hemolytic disease in Rh‑positive infants born to Rh‑negative mothers.

Common Side Effects: - Injection site pain or tenderness. - Mild fever or chills. - Headache. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Acute hemolysis. - Renal impairment or failure. - Thromboembolic events such as deep vein thrombosis.

Igamad should be administered only after confirming Rh‑negative status and assessing patient history.

Screening: verify Rh‑negative blood type before use. Allergy assessment: check for IgA deficiency or prior reactions to immunoglobulins. Pregnancy risk: use only when clinical benefit outweighs potential risk. Concurrent blood products: avoid mixing with RhD‑positive blood components without compatibility testing. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igamad may interact with other therapies that affect immune function or blood viscosity.

Major Interactions (Avoid): - Concurrent IVIG therapy: increased risk of hyperviscosity. - Live vaccines: possible interference with vaccine efficacy. - RhD‑positive blood products: may trigger hemolysis.

Moderate Interactions (Monitor Closely): - Corticosteroids: may mask early signs of allergic reaction. - Anticoagulants: monitor for bleeding if hemolysis occurs.